News & Events

Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced that Walter Piskorski has been appointed as Vice President, Technical Operations of Euthymics. Mr. Piskorski brings Euthymics four decades of biotechnology industry experience, and has spent the last 15 years in senior roles overseeing manufacturing operations.

Euthymics’ lead product candidate EB-1010 is a novel triple reuptake inhibitor antidepressant intended for use by the estimated two-thirds of major depression patients who do not respond adequately to the current medications available within the $20 billion worldwide antidepressant market. Mr. Piskorski will guide Euthymics as the company ramps up production to support the TRIADE—Triple Reuptake Inhibitor Anti-Depressant Effects—study, a Phase II/III clinical trial of EB-1010 in major depression planned for the first half of 2011.

“We are pleased to welcome to our senior management team Walt Piskorski, a longtime colleague who will give us the support and guidance on development and manufacturing we need as we move toward initiation of the TRIADE study,” said Anthony A. McKinney, President, CEO of Euthymics. “It is important that all elements of the TRIADE study, including good manufacturing practice, are executed correctly. Walt has a rich background and a record of success overseeing technical operations that we believe will lead to important contributions to Euthymics as our programs move forward.”

Mr. Piskorski’s experience with late-stage products includes Lunesta^®, Xopenex^® and Contrave^®. Most recently he served as Senior Vice President of Technical Operations at Orexigen Therapeutics, Inc., where he was in charge of manufacturing, quality, development and distribution, with a focus on Contrave which has been submitted to the FDA for obesity. Previously, Mr. Piskorski was Vice President of Manufacturing at Sepracor, Inc., where he directed all product manufacturing and distribution operations, and was involved in the commercialization of several successful products. Earlier in his career, Mr. Piskorski held manufacturing and business development positions at companies including Baxter Healthcare Corp. and Bristol-Myers Squibb.

In addition to Mr. Piskorski’s appointment, Euthymics announced that the company has moved into permanent headquarters in Cambridge, Massachusetts. Establishing permanent headquarters also supports Euthymics’ work toward achieving critical milestones planned in the remaining months of 2010 and the first half of 2011.